بدائل البحث:
largest decrease » larger decrease (توسيع البحث)
marked decrease » marked increase (توسيع البحث)
026 decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
9 026 » n 026 (توسيع البحث)
largest decrease » larger decrease (توسيع البحث)
marked decrease » marked increase (توسيع البحث)
026 decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
9 026 » n 026 (توسيع البحث)
-
1
-
2
-
3
-
4
-
5
-
6
Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf
منشور في 2025"…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …"
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
(A-H). Case 1: primary subcutaneous facial alveolar echinococcosis.
منشور في 2025"…<p><b>(A)</b> Left frontal swelling at diagnosis. <b>(B)</b> Marked regression of the lesion after 6 months of albendazole therapy. …"
-
16
-
17
Table 9_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx
منشور في 2024"…From 1990 to 2021, the number of epilepsy-related deaths and DALYs both decreased. However, the ASPR of epilepsy increased by about 6.9% (95% UI: −0.10–0.26), and the ASIR increased by almost 12% (95% UI: 0.05–0.33). …"
-
18
Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups.
منشور في 2025"…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"
-
19
-
20
Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…</p>Results<p>At baseline, the two groups were comparable in GFR (SGLT2i: 55.6 ± 1.9 vs. insulin: 58.1 ± 2.1 mL/min/1.73 m², p = 0.37), CKD stage, ARFI-SWV (2.9 ± 0.1 vs. 2.8 ± 0.1 m/s, p = 0.26), MELD-Na, and MELD 3.0. …"